<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>365</serviceExecutionTime><Drug id="6810"><DrugName>teceleukin</DrugName><DrugNamesKey><Name id="42770149">Imunace</Name><Name id="42922587">teceleukin</Name></DrugNamesKey><DrugSynonyms><Name><Value>S-6820</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Imunace</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Imunase</Value></Name><Name><Value>Bioleukin</Value></Name><Name><Value>IL-2, Biogen</Value></Name><Name><Value>IL-2, Shionogi</Value></Name><Name><Value>BG-8301, Biogen</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>interleukin-2, Biogen</Value></Name><Name><Value>interleukin-2, Shionogi</Value></Name><Name><Value>teceleukin</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>BG 8301</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14729">Biogen Inc (FL)</CompanyOriginator><CompaniesPrimary><Company id="1127603">KYOWA Pharmaceutical Industry Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="14729">Biogen Inc (FL)</Company><Company id="19898">Shionogi &amp; Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6810" type="Drug"><TargetEntity id="115007" type="siDrug">Teceleukin</TargetEntity></SourceEntity><SourceEntity id="1127603" type="Company"><TargetEntity id="5000013339" type="organizationId">Kyowa Pharmaceutical Industry Co Ltd</TargetEntity></SourceEntity><SourceEntity id="14729" type="Company"><TargetEntity id="5004622840" type="organizationId">Palm Harbour Inc</TargetEntity></SourceEntity><SourceEntity id="19898" type="Company"><TargetEntity id="4295876951" type="organizationId">Shionogi &amp; Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"></TargetEntity><TargetEntity id="D009362" type="MeSH"></TargetEntity><TargetEntity id="-1423187778" type="omicsDisease"></TargetEntity><TargetEntity id="618" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="194" type="ciIndication"><TargetEntity id="10039491" type="MEDDRA"></TargetEntity><TargetEntity id="D012509" type="MeSH"></TargetEntity><TargetEntity id="-172901782" type="omicsDisease"></TargetEntity><TargetEntity id="714" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="4" type="ciIndication"><TargetEntity id="10000565" type="MEDDRA"></TargetEntity><TargetEntity id="D000163" type="MeSH"></TargetEntity><TargetEntity id="-956122641" type="omicsDisease"></TargetEntity><TargetEntity id="1124" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="999" type="ciIndication"><TargetEntity id="C64" type="ICD10"></TargetEntity><TargetEntity id="10038389" type="MEDDRA"></TargetEntity><TargetEntity id="D007680" type="MeSH"></TargetEntity><TargetEntity id="-1866040075" type="omicsDisease"></TargetEntity><TargetEntity id="607" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="PTGT-03144" type="ciTarget"><TargetEntity id="10103482135583" type="siTarget">Interleukin-2</TargetEntity><TargetEntity id="398" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Cancer - Japan - Dec-1998</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="651">Cancer</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1069">Metastasis</Indication><Indication id="194">Sarcoma</Indication><Indication id="4">Acquired immune deficiency syndrome</Indication><Indication id="999">Renal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="12481">Interleukin-2 ligand</Action></ActionsPrimary><ActionsSecondary><Action id="393">Immunostimulant</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="1263">Immuno-oncology</Technology><Technology id="596">Injectable formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-07T07:38:33.000Z</LastModificationDate><ChangeDateLast>2019-06-07T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Teceleukin (S-6820), a recombinant human interleukin-2 (IL-2) product, has been developed and launched in Japan as Imunace by &lt;ulink linkID="19898" linkType="Company"&gt;Shionogi&lt;/ulink&gt; (under license from &lt;ulink linkID="14729" linkType="Company"&gt;Biogen&lt;/ulink&gt;), for the treatment of angiosarcoma and renal cancer [&lt;ulink linkID="177782" linkType="reference"&gt;177782&lt;/ulink&gt;], [&lt;ulink linkID="411971" linkType="reference"&gt;411971&lt;/ulink&gt;]. By 1998, the drug had been launched in Japan for  cancer [&lt;ulink linkID="1029648" linkType="Reference"&gt;1029648&lt;/ulink&gt;]. In July 2016, Shionogi announced that it was to transfer rights to  &lt;ulink linkID="1127603" linkType="Company"&gt;Kyowa Pharmaceutical Industry&lt;/ulink&gt;. The transfer took place on December 01, 2016 [&lt;ulink linkID="1785006" linkType="Reference"&gt;1785006&lt;/ulink&gt;], [&lt;ulink linkID="1784997" linkType="Reference"&gt;1784997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Shionogi was also developing teceleukin for the potential treatment of liver metastasis from colorectal cancer; by January 2001, the compound was in phase II development in Japan for this indication [&lt;ulink linkID="398750" linkType="reference"&gt;398750&lt;/ulink&gt;]. These phase II trials were ongoing in November 2004 [&lt;ulink linkID="491461" linkType="reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="618868" linkType="Reference"&gt;618868&lt;/ulink&gt;].  By January 2005, development had been terminated for this indication, as the studies had shown improvement in tumor size but not in survival rate [&lt;ulink linkID="595207" linkType="Reference"&gt;595207&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2001, it was reported that the compound was also being developed by &lt;ulink linkID="14729" linkType="Company"&gt;Biogen&lt;/ulink&gt;, for the potential treatment of AIDS; Shionogi was not involved in development [&lt;ulink linkID="411971" linkType="reference"&gt;411971&lt;/ulink&gt;]; however in March 2002, &lt;ulink linkID="14729" linkType="Company"&gt;Biogen&lt;/ulink&gt; confirmed that it was not developing the compound for any indication [&lt;ulink linkID="444027" linkType="reference"&gt;444027&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1127603">KYOWA Pharmaceutical Industry Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-01T00:00:00.000Z</StatusDate><Source id="1785006" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1069">Metastasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-01-31T00:00:00.000Z</StatusDate><Source id="595207" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14729">Biogen Inc (FL)</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="4">Acquired immune deficiency syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-03-19T00:00:00.000Z</StatusDate><Source id="444027" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14729">Biogen Inc (FL)</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2002-03-19T00:00:00.000Z</StatusDate><Source id="444027" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-01T00:00:00.000Z</StatusDate><Source id="1785006" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-01T00:00:00.000Z</StatusDate><Source id="1785006" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-01T00:00:00.000Z</StatusDate><Source id="1785006" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14729">Biogen Inc (FL)</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="4">Acquired immune deficiency syndrome</Indication><Source id="411971" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14729">Biogen Inc (FL)</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1995-01-01T00:00:00.000Z</StatusDate><Source id="177782" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1127603">KYOWA Pharmaceutical Industry Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-02T00:00:00.000Z</StatusDate><Source id="1785006" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="194">Sarcoma</Indication><Source id="411971" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1999-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19898">Shionogi &amp; Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1069">Metastasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-01-31T00:00:00.000Z</StatusDate><Source id="398750" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19898">Shionogi &amp; Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>In combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1990-05-11T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19898">Shionogi &amp; Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="1766">Renal cell carcinoma</Indication><AwardedIndication>In combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1990-05-03T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19898">Shionogi &amp; Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="3257">Stage IV melanoma</Indication><AwardedIndication>Treatment of metastatic malignant melanoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1990-02-06T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19898">Shionogi &amp; Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="1766">Renal cell carcinoma</Indication><AwardedIndication>Treatment of metastatic renal cell carcinoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1990-02-05T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-03144"><Name>Interleukin-2 ligand</Name><SwissprotNumbers><Swissprot>O62641</Swissprot><Swissprot>O77620</Swissprot><Swissprot>O97513</Swissprot><Swissprot>P04351</Swissprot><Swissprot>P05016</Swissprot><Swissprot>P17108</Swissprot><Swissprot>P19114</Swissprot><Swissprot>P26891</Swissprot><Swissprot>P36835</Swissprot><Swissprot>P37997</Swissprot><Swissprot>P46649</Swissprot><Swissprot>P51747</Swissprot><Swissprot>P60568</Swissprot><Swissprot>P60569</Swissprot><Swissprot>P68290</Swissprot><Swissprot>P68291</Swissprot><Swissprot>Q07885</Swissprot><Swissprot>Q08081</Swissprot><Swissprot>Q08867</Swissprot><Swissprot>Q29416</Swissprot><Swissprot>Q29615</Swissprot><Swissprot>Q5MBA8</Swissprot><Swissprot>Q7JFM3</Swissprot><Swissprot>Q7JFM4</Swissprot><Swissprot>Q7JFM5</Swissprot><Swissprot>Q865X2</Swissprot><Swissprot>Q865Y1</Swissprot><Swissprot>Q8MKH2</Swissprot><Swissprot>Q95KP3</Swissprot><Swissprot>Q9XS38</Swissprot><Swissprot>Q9XT83</Swissprot><Swissprot>Q9XT84</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1005244">Biogen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19898">Shionogi &amp; Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="21932">Lupin Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="127670" title="Shionogi to obtain exlcusive Japanese rights to teceleukin from Biogen"></Deal><Deal id="161743" title="Kyowa to acquire Shionogi's 21 drugs including cefaclor, lisinopril and teceleukin in Japan "></Deal></Deals><PatentFamilies><PatentFamily id="1423370" number="EP-00229016" title="Interleukin-2 Compositions"></PatentFamily><PatentFamily id="1862797" number="EP-00118977" title="Dna Sequences, Recombinant Dna Molecules And Processes For Producing Human Interleukin Two-Like Polypeptides"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biogen Inc" id="1005244"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shionogi &amp; Co Ltd" id="19898"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordsOutput>